Prescient Therapeutics Extends Share Purchase Plan to Fuel Cancer Drug Development

Prescient Therapeutics (ASX: PTX), an Australian biotech company specializing in targeted cancer therapies, has extended its Share Purchase Plan (SPP) to July 22, 2025. The initiative aims to raise up to AU$7 million to progress its lead compound PTX-100 through Phase 2 clinical trials. PTX-100, a first-in-class GGT-1 inhibitor, disrupts cancer cell growth pathways and has shown promising safety and efficacy in T cell lymphomas. The U.S. FDA has granted the therapy both Orphan Drug status and Fast Track designation. In addition, Prescient is advancing its CellPryme-M and CellPryme-A platforms to enhance CAR-T therapies, and developing OmniCAR, a modular immune receptor platform enabling multi-antigen targeting. These innovations underscore the company’s focus on personalized and controllable cell therapies. The SPP offers shares at a discounted price of AU$0.040 each, with applications open to eligible shareholders as of June 30, 2025

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com